Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Media
Press Releases - 2005
Newron Pharmaceuticals Completes €30 Million Series B Financing - TVM invests in second closing of HBM-led financing05/10/2005 | 
ENG
| ||
Newron Pharmaceuticals Completes Enrollment in Safinamide Phase III Pivotal Clinical Trial for Parkinson’s Disease21/07/2005 |
ENG
| ||
Newron Pharmaceuticals Completes Management Team with Appointment of Chief Financial Officer and Chief Medical Officer04/05/2005 |
ENG
| ||
Newron Pharmaceuticals Raises €30 Million21/02/2005 |
ENG
| ||
Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome11/01/2005 |
ENG
| 
ITA
|